Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCB-554
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
UCB-554 is a small molecule positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor (CHRM1). Developed by UCB, it was primarily investigated for the treatment of cognitive impairment associated with neurological and psychiatric disorders, such as Alzheimer's disease and schizophrenia. By selectively modulating the M1 receptor, UCB-554 aims to enhance cholinergic neurotransmission, which is critical for memory and learning, while potentially avoiding the side effects associated with non-selective muscarinic agonists. Clinical development reached Phase 1, where its safety, tolerability, and pharmacokinetics were evaluated in healthy volunteers.
02
Targets
M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on UCB-554.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCB-554.